Vall D'hebron Institute Of Oncology

This study tested whether combining two immunotherapy drugs (atezolizumab and bevacizumab) could shrink tumors in people with advanced colorectal cancer that had stopped responding to standard chemotherapy. The trial enrolled 46 adults whose cancer had a specific genetic signatur…

This early study tested whether adding donor immune cells (natural killer cells) to standard breast cancer drugs could help patients with advanced HER2-positive breast cancer that had stopped responding to previous treatments. The goal was to see if this combination was safe and …